Bonti kicks off Ph2 trial for neurotoxin pain-reliever

Privately-held biotech Bonti said today that it launched the Lantern clinical program, evaluating its intramuscular neurotoxin injection as a non-opioid pain reliever. The first clinical trial, Lantern-1, is a Phase II study designed to assess the safety and efficacy of EB-001 in patients undergoing elective breast augmentation. Get the full story at our sister site, Drug Delivery Business News. The post Bonti kicks off Ph2 trial for neurotoxin pain-reliever appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Biotech Clinical Trials Drug-Device Combinations Pain Management Pharmaceuticals bonti Source Type: news